Chinese Japanese Germany


Chemical Name:
ANANDRON;RU-23908;Nilandron;NILUTAMIDE;Nilandrone;nilutamida;RU 23908-10;Nilutamide(other anti-cancers);5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]hydantoin;1-3-Trifluoromethyl-4-nitrophenyl)-4,4-dimethylimidazoline-2,5-dione
Molecular Formula:
Formula Weight:
MOL File:

Nilutamide Properties

Melting point:
storage temp. 
Store at RT
Very slightly soluble in water, freely soluble in acetone, soluble in anhydrous ethanol.
CAS DataBase Reference
63612-50-0(CAS DataBase Reference)
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  T
Risk Statements  60-25
Safety Statements  53-36/37/39-45
RIDADR  UN 2811 6.1/PG 3
WGK Germany  3
RTECS  NI9453300
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H301 Toxic if swalloed Acute toxicity,oral Category 3 Danger P264, P270, P301+P310, P321, P330,P405, P501
H360 May damage fertility or the unborn child Reproductive toxicity Category 1A, 1B Danger
Precautionary statements:
P201 Obtain special instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P308+P313 IF exposed or concerned: Get medical advice/attention.

Nilutamide price More Price(5)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich N8534 Nilutamide 63612-50-0 1g $81.9 2018-11-20 Buy
Sigma-Aldrich Y0000829 Nilutamide European Pharmacopoeia (EP) Reference Standard 63612-50-0 y0000829 $179 2018-11-23 Buy
Cayman Chemical 23953 Nilutamide ≥98% 63612-50-0 500mg $40 2018-11-19 Buy
Cayman Chemical 23953 Nilutamide ≥98% 63612-50-0 1g $76 2018-11-19 Buy
Cayman Chemical 23953 Nilutamide ≥98% 63612-50-0 5g $360 2018-11-19 Buy

Nilutamide Chemical Properties,Uses,Production

Chemical Properties

Crystalline Solid


The second nonsteroidal anti-androgen to be marketed was nilutamide. It was discovered from a series of flutamide analogues at Roussel Uclaf (now Sanofi) in the 1970s using a rat prostate assay determining the inhibition of androgen uptake.The investigational compound code was RU 23908. Its structure is closely related to hydroxyflutamide, particularly under the assumption that the α-hydroxyamide engages in an internal hydrogen bond when bound to the AR LBD. The hydantoin moiety of nilutamide mimics the active conformation of hydroxyflutamide.
Like flutamide, nilutamide blocks the action of androgens originating from both testis and adrenal. It also has neither agonist nor any other hormonal activity. Nilutamide has an elimination half-life of approximately 2 days in patients, which is significantly longer than that of flutamide. Thus, a single oral dose of 150 mg daily was feasible.


Nonsteroidal antiandrogen. Antineoplastic (hormonal)


Clinical trials with nilutamide were conducted predominantly in combination with orchiectomy. Results indicated retardation of disease progression and relief of metastatic bone pain in patientswith advanced prostate cancer.However, patient survival benefit was small compared with castration alone. Studies of nilutamide monotherapy or combination with LHRH agonists did not have sufficient patient numbers to allow reliable conclusions on efficacy. Nilutamide was first launched in France in 1987 for treatment of metastatic prostate cancer in adjuvant therapy with surgical castration. Approval in several major markets was granted in the following years.
The tolerability profile of nilutamide was similar to that of flutamide. Hot flushes, nausea, diarrhea, constipation, gastrointestinal pain, abnormal liver function, and gynecomastia were frequently reported adverse events with both drugs. Additional side effects were predominantly associated with nilutamide treatment: interstitial pneumonitis, impaired adaptation to darkness, and alcohol intolerance.
The nonsteroidal anti-androgens flutamide and nilutamide established combined androgen blockade as first-line treatment for metastatic prostate cancer. Still, there was room for improvement with regard to overall survival (OS) and tolerability.

brand name

Nilandron (Sanofi Aventis).

Biological Activity

Non-steroidal and silent antiandrogen. Binds to androgen receptors and also inhibits androgen biosynthesis in vitro . In rats in vivo it inhibits androgen-induced prostate weight increase and inhibits negative androgen-dependent gonadotropin feedback leading to an increase in luteinising hormone and testosterone. Orally active.

Nilutamide Preparation Products And Raw materials

Raw materials

Preparation Products

Nilutamide Suppliers

Global( 92)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19953 60
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32651 55
020-81716319 CHINA 2548 55
SHANGHAI YINGRUI CHEMICAL TECHNOLOGY CO.,LTD. 021-34666753 33588661 33585969 33585366 13311639313 400-615-1668
+86-21-34979012 China 2135 55
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933; China 96815 76
3B Pharmachem (Wuhan) International Co.,Ltd. 86-21-50328103 * 801、802、803、804 Mobile:18930552037
86-21-50328109 China 15926 69
Capot Chemical Co., Ltd +86 (0) 571 85 58 67 18
0086-571-85864795 China 18274 66
JinYan Chemicals(ShangHai) Co.,Ltd. 13817811078,021-50426030
86-021-50426522,50426273 China 10073 60
Chemfun Medical Technology(Shanghai) Co., Ltd. 021-67220633 & 021-37212706
+86-21-67220638 China 21889 59
LGM Pharma 1-(800)-881-8210
615-250-9817 United States 1954 70

63612-50-0(Nilutamide)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved